The addition of bevacizumab to temozolomide-based therapy was associated with an improvement in overall response (OR) in children with relapsed/refractory neuroblastoma enrolled in the phase 2 BEACON-Neuroblastoma clinical trial.
Patients with relapsed or refractory neuroblastoma aged 1- 21 years were randomly assigned to receive treatment in 5 experimental arms: temozolomide-bevacizumab; irinotecan-temozolomide; irinotecan-temozolomide-bevacizumab; temozolomide-topotecan; and topotecan-temozolomide.
The primary end point for part 1 (n=106) of the study was best response, with at least 4 more responses in the bevacizumab plus chemotherapy arms compared with the chemotherapy alone arms set as the criterion for a positive result. In total, 17 of 52 patients (33%) receiving chemotherapy plus bevacizumab and 8 of 54 patients (15%) receiving chemotherapy alone had an objective response to trea...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« PFS benefit with niraparib as first-line maintenance in ovarian cancer Next Article
Larotrectinib: safe and effective in TRK fusion-positive tumours »
Table of Contents: ESMO 2019
Solid tumours/pan-tumour data
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.